Aurinia Pharmaceuticals Inc. (IKAP)

Market Closed

20 Feb, 20:00

XFRA

€

12. 11

-0.01

-0.08%

- Market Cap

- P/E Ratio

- Div Yield

250 Volume

-0.52 Eps

€ 12.12

Previous Close

Day Range

12.04 12.11

Year Range

6.19 14.27

Want to track IKAP and more in your Portfolio? 🎯

Get Started For Free

IKAP earnings report is expected in 2 days (26 Feb 2026)

Summary

IKAP closed Friday lower at €12.11, a decrease of 0.08% from Thursday's close, completing a monthly increase of 1.59% or €0.19. Over the past 12 months, IKAP stock lost -9.25%.

IKAP is not paying dividends to its shareholders.

The last earnings report, released on Nov 06, 2025, missed the consensus estimates by -0.16%. On average, the company has fell short of earnings expectations by -0.05%, based on the last three reports. The next scheduled earnings report is due on Feb 26, 2026.

Aurinia Pharmaceuticals Inc. has completed 1 stock splits, with the recent split occurring on Oct 23, 2013.

The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

IKAP Chart

Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks | 1 month ago

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks | 2 months ago

What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now?

Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 2 months ago

Aurinia Pharmaceuticals Inc. (IKAP) FAQ

What is the stock price today?

The current price is €12.11.

On which exchange is it traded?

Aurinia Pharmaceuticals Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is IKAP.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.22.

When is the next earnings date?

The next earnings report will release on Feb 26, 2026.

Has Aurinia Pharmaceuticals Inc. ever had a stock split?

Aurinia Pharmaceuticals Inc. had 1 splits and the recent split was on Oct 23, 2013.

Aurinia Pharmaceuticals Inc. Profile

Biotechnology Industry	Healthcare Sector	Peter S. Greenleaf CEO	XFRA Exchange	CA05156V1022 ISIN
CA Country	130 Employees	- Last Dividend	23 Oct 2013 Last Split	26 Jan 1999 IPO Date

Overview

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company established in 1993 and based in Edmonton, Canada. The company dedicates its efforts to developing and commercializing innovative therapies intended to address diseases with significant unmet medical needs within the United States. Through its focus on specialized medication, Aurinia Pharmaceuticals has positioned itself as a key player in the healthcare industry, particularly in the realm of treatment for complex diseases. Its partnership with Otsuka Pharmaceutical Co., Ltd. underlines its commitment to expanding its reach and enhancing the impact of its therapeutic solutions on patients' lives.

Products and Services

LUPKYNIS - This product is designed for the treatment of adult patients suffering from active lupus nephritis, a serious autoimmune disease that affects the kidneys. Aurinia Pharmaceuticals has successfully brought LUPKYNIS to the commercial stage, offering hope and a much-needed solution to individuals dealing with this challenging condition. The availability of LUPKYNIS underscores the company's focus on addressing diseases that have historically had limited treatment options.

Contact Information

Address: 4464 Markham Street

Phone: 12507084272

Website: https://www.auriniapharma.com

Affiliate Program About Terms Privacy Help Contact Us